Seres Therapeutics Cuts Costs Amid Promising irEC Trial Data
Event summary
- 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 in an irEC trial conducted by MSK.
- Seres announced early termination of its Sidney Street lease to reduce ongoing facility-related cash costs beginning in 2027.
- The company reported net income of $4.6 million for Q2 2026, compared to a net loss of $19.9 million in the same period last year.
- Seres received $12.5 million from Nestlé Health Science and expects another $12.5 million by October 1, 2026.
The big picture
Seres Therapeutics is navigating a strategic pivot, balancing cost reductions with the advancement of its live biotherapeutics pipeline. The promising irEC trial data positions SER-155 as a potential treatment that could allow patients to continue cancer therapy, while financial restructuring aims to strengthen the company's balance sheet amid ongoing operational challenges.
What we're watching
- Clinical Development Strategy
- How Seres will leverage the positive irEC trial data to secure partnerships and advance SER-155 development.
- Financial Sustainability
- Whether the cost-cutting measures and milestone payments will extend the company's cash runway beyond Q1 2027.
- Pipeline Advancement
- The pace at which Seres can progress its broader inflammatory and immune portfolio, including SER-603 for IBD.
Related topics